Tumor-focused Parabilis raises $305M to upend status quo Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable . . . Founded as FogPharma in 2015 by serial biotech entrepreneur Gregory Verdine, Parabilis has raised more than $800 million in private funding and has so far spent nearly $600 million on drug research, according to its IPO filing
Parabilis Medicines | The Pharma Letter | The Pharmaletter Formerly known as FogPharma, the company rebranded as Parabilis Medicines to reflect its evolution toward a broader pipeline and clinical identity Parabilis is focused exclusively on oncology, pursuing targets that small molecules and biologics have repeatedly failed to engage
Government Contract Financing | Parabilis We provide financial partnerships for government contractors in winning federal contract bids and extending business lines of credit
Parabilis Medicines - LinkedIn Parabilis Medicines™ is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein
Parabilis Space Technologies Named from the Latin word parabilis (meaning “easily obtainable”), Parabilis is redefining how propulsion solutions are delivered for space and airborne systems